Recombinant hepatitis B vaccine and the risk of multiple sclerosis

  title={Recombinant hepatitis B vaccine and the risk of multiple sclerosis},
  author={Miguel A. Hern{\'a}n and Susan S. Jick and Michael J. Olek and Hershel Jick},
  pages={838 - 842}
Background: A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations. Methods: The authors conducted a nested case-control study within the General Practice Research Database (GPRD) in the United Kingdom. The authors identified patients who had a first MS diagnosis recorded in the GPRD between January 1993 and December 2000. Cases were patients… 

Tables from this paper

Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood
Hepatitis B vaccination does not generally increase the risk of CNS inflammatory demyelination in childhood, however, the Engerix B vaccine appears to increase this risk, particularly for confirmed multiple sclerosis, in the longer term.
Does the hepatitis B vaccine cause multiple sclerosis?
The Hernan paper used the General Practice Research Database of the United Kingdom to ascertain 163 cases of confirmed MS, and performed a case-controlled analysis for the association of first MS symptoms with HBV, identifying 11 people who developed first symptoms of MS within 3 years of the vaccine.
Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.
The findings support clinical anecdotes of CNS ADS symptom onset shortly after vaccination but do not suggest a need for a change in vaccine policy.
Hepatitis B vaccine and multiple sclerosis: A case of repeated dejavu?
To the Editor: I cannot agree more with Braillon [1] that in revealing the results of any study concerning the adverse reactions of treatment or prevention measures, everyone in the chain of
Tetanus vaccination and risk of multiple sclerosis
Tetanus vaccination is associated with a lower risk of multiple sclerosis, and there was little indication of heterogeneity of results across studies.
Antibiotic use and risk of multiple sclerosis.
Overall antibiotic use or use of antibiotics against C. pneumoniae was not associated with multiple sclerosis risk, and use of penicillins in the 3 years before the index date decreased the risk of developing a first attack of multiple sclerosis.
Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production
A critical systematic review aimed at assessing whether hepatitis B vaccination increases the risk of onset or relapse of multiple sclerosis and other central nervous system demyelinating diseases concluded that on the basis of current data there is no need to modify the vaccination recommendations.
Immunizations and risk of multiple sclerosis: systematic review and meta-analysis
Risk of developing multiple sclerosis remained unchanged after BCG, Hepatitis B, Influenza, MMR, Polio and Typhoid fever immunization, whereas diphtheria and tetanus vaccination may be associated with a decreased risk of MS.


Hepatitis B vaccination and the risk of multiple sclerosis.
A nested case-control study in two large cohorts of nurses in the United States indicates no association between hepatitis B vaccination and the development of multiple sclerosis.
Hepatitis B Vaccination and First Central Nervous System Demyelinating Event: A Case-Control Study
This study was sufficiently powerful to rule out a strong association between HB vaccine exposure and a subsequent demyelinating event, however, it could not provide a clear indication of a moderately increased risk of a CNS demyELinating event shortly after HB vaccination in adults.
Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases.
The results of this study do not provide strong arguments for ruling out the possibility of an association, causal or otherwise, between HB vaccine and first episode of central nervous system demyelinating disorders, and the underreporting coefficient is not significantly different from that expected at the 5% level.
Vaccinations and risk of central nervous system demyelinating diseases in adults.
Vaccination against hepatitis B, influenza, tetanus, measles, or rubella is not associated with an increased risk of multiple sclerosis or optic neuritis.
The epidemiology of multiple sclerosis: A general overview
  • C. Poser
  • Medicine, Psychology
    Annals of neurology
  • 1994
The concept of onset‐adjusted prevalence suggests that patients who are symptomatic should be included retrospectively in epidemiological surveys, even before they have been formally diagnosed as having MS, but individuals who were symptomatic before moving to a study area should not.
Drug abuse as a risk factor of multiple sclerosis: case-control analysis and a study of heterogeneity.
Three main groups of MS subjects were obtained from the cluster analysis, distinguished by the gender, the presence or not of family history and the degree of severity of their physical disability, showing that drug abuse was the only risk factor with a statistically significant odds ratio for overall and for the unique female group without familial history of MS.
Audit of hepatitis B immunization at the genitourinary medicine department in Middlesbrough, UK
The outcomes of hepatitis B immunization programme at the genitourinary medicine (GUM) department in Middlesbrough during a period of five years were examined. The majority of those immunized were
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
Use of the UK General Practice Research Database for pharmacoepidemiology.
The General Practice Research Database in the UK has proved that valuable data can be collected in a general practice setting and should serve to encourage others to develop similar population-based data in other countries.